Reviewing OKYO Pharma (NASDAQ:OKYO) and Immunovant (NASDAQ:IMVT)

Immunovant (NASDAQ:IMVT) and OKYO Pharma (NASDAQ:OKYO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Insider and Institutional Ownership

47.1% of Immunovant shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 5.9% of Immunovant shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Immunovant and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-77.94%	-69.82%
OKYO Pharma	N/A	N/A	N/A

Valuation and Earnings

This table compares Immunovant and OKYO Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$259.34 million	($2.62)	-7.86
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A

Risk and Volatility

Immunovant has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Immunovant and OKYO Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	0	1	10	1	3.00
OKYO Pharma	0	0	1	0	3.00

Immunovant currently has a consensus target price of $45.90, indicating a potential upside of 122.82%. OKYO Pharma has a consensus target price of $7.00, indicating a potential upside of 455.60%. Given OKYO Pharma’s higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Immunovant.

Summary

OKYO Pharma beats Immunovant on 5 of the 9 factors compared between the two stocks.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.